Joseph Echevarria - Pfizer Independent Director
PFE Stock | USD 28.82 0.44 1.55% |
Director
Mr. Joseph J. Echevarria is an Independent Director of Pfizer Inc.. Mr. Echevarria was Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporationrationration, Unum Group, a provider of financial protection benefits, and Xerox Corporationrationration. Member of the Presidents Export Council and former member of the Presidential Commission on Election Administration. Chair Emeritus of My Brothers Keeper Alliance. Member of the Board of Trustees of the University of Miami. Mr. Echevarrias 36year career at Deloitte brings financial expertise and international business, leadership and risk management skills to the Board. Mr. Echevarrias financial acumen, including his significant previous audit experience, expertise in accounting issues and service on the audit committee of another public company, is an asset to Pfizers Board and Audit Committee. Pfizer also benefits from Mr. Echevarrias breadth and diversity of experience, which includes his public service on the Presidents Export Council. since 2015.
Age | 64 |
Tenure | 9 years |
Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
As of May 16, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 7 records | DIRECTOR Age | ||
Byungho Lee | LG Display Co | N/A | |
Julie Schneekloth | United Fire Group | N/A | |
Geun Han | LG Display Co | 63 | |
Jin Jang | LG Display Co | 64 | |
Seong Hwang | LG Display Co | 63 | |
Sung Hwang | LG Display Co | N/A | |
ChangYang Lee | LG Display Co | N/A |
Management Performance
Return On Equity | -0.0026 | ||||
Return On Asset | 0.0093 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
Shantanu Narayen, Lead Independent Director | ||
James Smith, Independent Director | ||
Christopher CFA, VP Officer | ||
Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
Susan DesmondHellmann, Independent Director | ||
Francesca DeMartino, Chief Officer | ||
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
Gordon Loh, Senior Vice President Corporate Audit | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
DVM DVM, Chairman CEO | ||
William Gray, Independent Director | ||
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
Susan Hockfield, Independent Director | ||
William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
Mikael MD, Chief Development | ||
Albert DVM, Chairman CEO | ||
Dan Littman, Independent Director | ||
Payal Becher, Chief VP | ||
James Kilts, Independent Director | ||
James Quincey, Independent Director | ||
Andreas Panayiotou, Global Officer | ||
Joseph Echevarria, Independent Director | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Scott Gottlieb, Independent Director | ||
Ronald Blaylock, Independent Director |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0026 | ||||
Return On Asset | 0.0093 | ||||
Profit Margin | (0.01) % | ||||
Operating Margin | 0.32 % | ||||
Current Valuation | 219.07 B | ||||
Shares Outstanding | 5.67 B | ||||
Shares Owned By Insiders | 0.04 % | ||||
Shares Owned By Institutions | 69.06 % | ||||
Number Of Shares Shorted | 62.51 M | ||||
Price To Earning | 9.48 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Dividend Share 1.65 | Earnings Share (0.05) | Revenue Per Share 9.717 | Quarterly Revenue Growth (0.20) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.